©2024 Stanford Medicine
Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Recruiting
I'm InterestedTrial ID: NCT05050149
Purpose
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in
the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months
of PTX-022 treatment by the end of the study.
Official Title
A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations
Stanford Investigator(s)
Joyce Teng, MD, PhD
Professor of Dermatology and, by courtesy, of Pediatrics
Eligibility
Inclusion Criteria:
- Participants must be 13 years or older
- Diagnosed with Microcystic Lymphatic Malformations
- Able and willing to comply with all protocol-required activities
- Willing and able to provide written informed consent
Exclusion Criteria:
- Any significant concurrent condition that could adversely affect participation.
- Any history of allergy or hypersensitivity to sirolimus, or sirolimus-like medications
or to PTX-022
- Patient's deemed by the investigator as unwilling or unable to remain compliant with
all tests and procedures, including adherence to study drug administration and other
protocol-required activities.
Intervention(s):
drug: PTX-022
Recruiting
I'm InterestedContact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Pediatric Dermatology Research
650-723-0636